Steven Russell, MD
Endocrinology, Diabetes & Metabolism · Boston, MANPI 1679554042
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $348,152 of the $444,706 with a category attached, or 78.3%. Medtronic accounts for 85.2% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $370,070 and has fallen 99.7% since, to $1,154 in 2025. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 55 payments — averaging $8085.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$379K
- Novo Nordisk AS$35K
- Novo Nordisk$23K
- Convatec Inc.$5K
- Lilly USA, LLC$2K
- Dexcom, Inc.$308
- plus $832 from 5 others
Across 24 payments — averaging $25,789 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$618K
- Dexcom, Inc.$1K
What the payments were for
- Royalty or licence$348,15278%
- Consulting fees$33,5638%
- Speaking & faculty fees$2400%
- Grants$570%
- Travel & lodging$29,7657%
- Food & beverage$1,3860%
- Education$8500%
- Gifts$1190%
- Other$30,5747%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 6 | $378,782 |
| Novo Nordisk AS | 24 | $34,881 |
| Novo Nordisk | 9 | $22,945 |
| Convatec Inc. | 4 | $5,120 |
| Lilly USA, LLC | 1 | $1,838 |
| Dexcom, Inc. | 4 | $308 |
| BETA Bionics, Inc. | 2 | $283 |
| Senseonics, Incorporated | 1 | $240 |
| Mannkind Corporation | 2 | $119 |
| Zealand Pharma A/s | 1 | $100 |
| Abbott | 1 | $90 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- InPen$363,162
- INPEN SMART INSULIN DELIVERY SYSTEM$15,564
- FIASP$7,328
- Ryzodeg 70/30$6,698
- AQUACEL AG$2,880
- AQUACEL Ag Advantage Surgical$2,240
- iLet Bionic Pancreas$555
- Eversense$240
- Dasiglucagon$100
How this compares
$444,706 in reported general payments places this provider in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Boston
- Jason GagliaBoston$2.4M
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Augusto Caballero-RoblesBoston$150K
- Osama HamdyBoston$117K
- Barbara KahnBoston$105K
- Naomi FisherBoston$79K
- Andrea CovielloBoston$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.